About DNA Synthesis & Gene Editing
The DNA Synthesis & Gene Editing category is part of the Synthetic Biology market map, tracking 16 companies building in this segment. DNA synthesis, biomanufacturing, lab automation, and computational biology programming biology like software. Curated by Hartmann Capital's venture research team.
Companies in DNA Synthesis & Gene Editing
- Twist Bioscience — Public, $903M
- Ginkgo Bioworks — Public, $2.8B
- GenScript — Public, $595M
- Integrated DNA Technologies — Acquired
- Synthego — Series E, $497M
- Inscripta — Series E, $626M
- Mammoth Biosciences — Series D, $400M
- Ansa Biotechnologies — Series B, $122M
- Evonetix — Series B, $54M
- Ribbon Biolabs — Series A, $20M
- DNA Script — Series C, $225M
- Camena Bioscience — Series A, $10M
- Molecular Assemblies — Series B, $26M
- Constructive Bio — Series A, $73M
- Metagenomi — Public, $457M
- Atlas Data Storage — Seed, $155M
Frequently Asked Questions
- What companies are in the DNA Synthesis & Gene Editing category?
- The DNA Synthesis & Gene Editing category includes 16 companies: Twist Bioscience, Ginkgo Bioworks, GenScript, Integrated DNA Technologies, Synthego, Inscripta, Mammoth Biosciences, Ansa Biotechnologies, Evonetix, Ribbon Biolabs, DNA Script, Camena Bioscience, Molecular Assemblies, Constructive Bio, Metagenomi, Atlas Data Storage. This is part of the Synthetic Biology market map maintained by Hartmann Capital.
- How many DNA Synthesis & Gene Editing startups are tracked?
- Hartmann Capital tracks 16 companies in the DNA Synthesis & Gene Editing segment of the Synthetic Biology market map.
- What are the best funded DNA Synthesis & Gene Editing companies?
- Top funded companies in DNA Synthesis & Gene Editing include Ginkgo Bioworks ($2800M), Twist Bioscience ($903M), Inscripta ($626M), GenScript ($595M), Synthego ($497M). Browse the full list in the Synthetic Biology market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.